GENF vs. IMM, HEMO, CIZ, EVG, MTFB, BSFA, DEST, VAL, RENE, and ROQ
Should you be buying Genflow Biosciences stock or one of its competitors? The main competitors of Genflow Biosciences include ImmuPharma (IMM), Hemogenyx Pharmaceuticals (HEMO), Cizzle Biotechnology (CIZ), Evgen Pharma (EVG), Motif Bio (MTFB), BSF Enterprise (BSFA), Destiny Pharma (DEST), ValiRx (VAL), ReNeuron Group (RENE), and Roquefort Therapeutics (ROQ). These companies are all part of the "biotechnology" industry.
Genflow Biosciences vs. Its Competitors
ImmuPharma (LON:IMM) and Genflow Biosciences (LON:GENF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.
ImmuPharma has a net margin of 3,519.56% compared to Genflow Biosciences' net margin of 778.46%. ImmuPharma's return on equity of -131.41% beat Genflow Biosciences' return on equity.
6.1% of ImmuPharma shares are held by institutional investors. Comparatively, 0.8% of Genflow Biosciences shares are held by institutional investors. 9.7% of ImmuPharma shares are held by insiders. Comparatively, 42.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
ImmuPharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Genflow Biosciences has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.
ImmuPharma is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, ImmuPharma had 1 more articles in the media than Genflow Biosciences. MarketBeat recorded 1 mentions for ImmuPharma and 0 mentions for Genflow Biosciences. ImmuPharma's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.
Summary
ImmuPharma and Genflow Biosciences tied by winning 5 of the 10 factors compared between the two stocks.
Get Genflow Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GENF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genflow Biosciences Competitors List
Related Companies and Tools
This page (LON:GENF) was last updated on 8/31/2025 by MarketBeat.com Staff
